Fetal survival during gestation implies that tolerance mechanisms suppress the maternal immune response to paternally inherited alloantigens. Here we show that the inhibitory T cell costimulatory molecule, programmed death ligand 1 (PDL1), has an important role in conferring fetomaternal tolerance in an allogeneic pregnancy model. Blockade of PDL1 signaling during murine pregnancy resulted in increased rejection rates of allogeneic concepti but not syngeneic concepti. Fetal rejection was T cell– but not B cell–dependent because PDL1-specific antibody treatment caused fetal rejection in B cell–deficient but not in RAG-1–deficient females. Blockade of PDL1 also resulted in a significant increase in the frequency of IFN-γ–producing lymphocytes in response to alloantigen in an ELISPOT assay and higher IFN-γ levels in placental homogenates by ELISA. Finally, PDL1-deficient females exhibited decreased allogeneic fetal survival rates as compared with littermate and heterozygote controls and showed evidence of expansion of T helper type 1 immune responses in vivo. These results provide the first evidence that PDL1 is involved in fetomaternal tolerance.
Skip Nav Destination
Article navigation
18 July 2005
Article Contents
Brief Definitive Report|
July 18 2005
A critical role for the programmed death ligand 1 in fetomaternal tolerance
Indira Guleria,
Indira Guleria
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Arezou Khosroshahi,
Arezou Khosroshahi
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Mohammed Javeed Ansari,
Mohammed Javeed Ansari
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Antje Habicht,
Antje Habicht
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Miyuki Azuma,
Miyuki Azuma
3Department of Molecular Immunology, Tokyo Medical and Dental University, Tokyo 113-8549, Japan
Search for other works by this author on:
Hideo Yagita,
Hideo Yagita
4Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
Search for other works by this author on:
Randolph J. Noelle,
Randolph J. Noelle
5Dartmouth College, Hanover, NH 03755
Search for other works by this author on:
Anthony Coyle,
Anthony Coyle
6Millennium Pharmaceutical Inc., Cambridge, MA 02139
Search for other works by this author on:
Andrew L. Mellor,
Andrew L. Mellor
7Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia, Augusta, GA 309012
Search for other works by this author on:
Samia J. Khoury,
Samia J. Khoury
2Center for Neurologic Diseases, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Mohamed H. Sayegh
Mohamed H. Sayegh
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Indira Guleria
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Arezou Khosroshahi
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Mohammed Javeed Ansari
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Antje Habicht
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Miyuki Azuma
3Department of Molecular Immunology, Tokyo Medical and Dental University, Tokyo 113-8549, Japan
Hideo Yagita
4Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
Randolph J. Noelle
5Dartmouth College, Hanover, NH 03755
Anthony Coyle
6Millennium Pharmaceutical Inc., Cambridge, MA 02139
Andrew L. Mellor
7Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia, Augusta, GA 309012
Samia J. Khoury
2Center for Neurologic Diseases, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
Mohamed H. Sayegh
1Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115
CORRESPONDENCE Indira Guleria: [email protected]
Received:
January 03 2005
Accepted:
June 14 2005
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2005
J Exp Med (2005) 202 (2): 231–237.
Article history
Received:
January 03 2005
Accepted:
June 14 2005
Citation
Indira Guleria, Arezou Khosroshahi, Mohammed Javeed Ansari, Antje Habicht, Miyuki Azuma, Hideo Yagita, Randolph J. Noelle, Anthony Coyle, Andrew L. Mellor, Samia J. Khoury, Mohamed H. Sayegh; A critical role for the programmed death ligand 1 in fetomaternal tolerance . J Exp Med 18 July 2005; 202 (2): 231–237. doi: https://doi.org/10.1084/jem.20050019
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement